First Citizens Bank & Trust Co. acquired a new stake in shares of Shire PLC (NASDAQ:SHPG) during the second quarter, Holdings Channel reports. The firm acquired 2,043 shares of the biopharmaceutical company’s stock, valued at approximately $376,000.
Other institutional investors have also recently added to or reduced their stakes in the company. UBS Group AG raised its position in Shire PLC by 1,825.2% in the first quarter. UBS Group AG now owns 1,227,631 shares of the biopharmaceutical company’s stock valued at $211,030,000 after buying an additional 1,163,865 shares in the last quarter. Rockefeller Financial Services Inc. raised its position in Shire PLC by 142.7% in the second quarter. Rockefeller Financial Services Inc. now owns 615,314 shares of the biopharmaceutical company’s stock valued at $113,266,000 after buying an additional 361,743 shares in the last quarter. UBS Asset Management Americas Inc. raised its position in Shire PLC by 796.2% in the first quarter. UBS Asset Management Americas Inc. now owns 290,929 shares of the biopharmaceutical company’s stock valued at $50,011,000 after buying an additional 258,466 shares in the last quarter. OLD Mission Capital LLC purchased a new position in Shire PLC during the first quarter valued at $28,179,000. Finally, Sphera Funds Management LTD. raised its position in Shire PLC by 371.7% in the first quarter. Sphera Funds Management LTD. now owns 188,676 shares of the biopharmaceutical company’s stock valued at $16,479,000 after buying an additional 148,676 shares in the last quarter. 24.30% of the stock is currently owned by institutional investors and hedge funds.
Shares of Shire PLC (NASDAQ:SHPG) traded up 2.64% on Tuesday, reaching $190.70. The company’s stock had a trading volume of 3,228,601 shares. Shire PLC has a 52 week low of $147.60 and a 52 week high of $231.32. The stock has a market capitalization of $56.80 billion, a price-to-earnings ratio of 39.63 and a beta of 1.16. The stock has a 50-day moving average of $194.55 and a 200 day moving average of $188.26.
Shire PLC (NASDAQ:SHPG) last announced its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.35. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The firm earned $2.43 million during the quarter, compared to the consensus estimate of $2.28 billion. During the same quarter in the prior year, the company earned $2.63 EPS. The firm’s revenue for the quarter was up 55.9% compared to the same quarter last year. On average, analysts expect that Shire PLC will post $12.92 EPS for the current year.
The firm also recently announced a dividend, which was paid on Friday, October 7th. Investors of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s payout ratio is 15.63%.
SHPG has been the topic of several research analyst reports. Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Shire PLC in a research note on Tuesday, June 28th. Jefferies Group reiterated a “buy” rating and set a $262.00 target price on shares of Shire PLC in a report on Wednesday, September 7th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Shire PLC in a report on Monday, September 26th. TheStreet downgraded Shire PLC to a “hold” rating in a report on Thursday, August 4th. Finally, Citigroup Inc. reiterated a “buy” rating on shares of Shire PLC in a report on Friday, July 15th. Five investment analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $228.15.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.